CA3073718A1 - Ocular pharmaceutical compositions - Google Patents

Ocular pharmaceutical compositions Download PDF

Info

Publication number
CA3073718A1
CA3073718A1 CA3073718A CA3073718A CA3073718A1 CA 3073718 A1 CA3073718 A1 CA 3073718A1 CA 3073718 A CA3073718 A CA 3073718A CA 3073718 A CA3073718 A CA 3073718A CA 3073718 A1 CA3073718 A1 CA 3073718A1
Authority
CA
Canada
Prior art keywords
compound
active agent
formula
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073718A
Other languages
English (en)
French (fr)
Inventor
Alan Verkman
Marc H. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3073718A1 publication Critical patent/CA3073718A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3073718A 2017-08-24 2018-08-24 Ocular pharmaceutical compositions Pending CA3073718A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
CA3073718A1 true CA3073718A1 (en) 2019-02-28

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073718A Pending CA3073718A1 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions

Country Status (8)

Country Link
US (3) US11839616B2 (enExample)
EP (1) EP3672598A4 (enExample)
JP (1) JP2020531511A (enExample)
KR (1) KR20200044873A (enExample)
CN (1) CN111629730A (enExample)
AU (1) AU2018321926B2 (enExample)
CA (1) CA3073718A1 (enExample)
WO (1) WO2019040919A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102733897B1 (ko) 2015-12-24 2024-11-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
EP4069195A1 (en) * 2019-12-05 2022-10-12 Vanda Pharmaceuticals Inc. Ophthalmic pharmaceutical compositions
AU2021338837A1 (en) * 2020-09-10 2023-04-06 Vanda Pharmaceuticals Inc. Methods of treating PDE IV mediated diseases or conditions
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
WO1999038497A2 (en) * 1998-01-30 1999-08-05 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
JP2003519143A (ja) 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
RS34004A (sr) 2001-09-21 2006-10-27 Reddy Us Therapeutics Inc. Postupci i sastavi novih triazin jedinjenja
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2004031184A1 (en) 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP1716122B1 (en) 2004-01-30 2017-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
EP2037924A2 (en) 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009091388A2 (en) 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof
EA021904B1 (ru) 2008-03-05 2015-09-30 Мерк Патент Гмбх Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
KR20190061096A (ko) 2010-04-22 2019-06-04 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
EA201591175A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr
PE20160286A1 (es) * 2013-08-08 2016-05-22 Galapagos Nv DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3347912A1 (de) 2015-09-11 2018-07-18 ION-TOF Technologies GmbH Sekundärionen-massenspektrometer und sekundärionen-massenspektrometrisches verfahren
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
PL3394046T3 (pl) 2015-12-24 2022-06-13 The Regents Of The University Of California Regulatory cftr i sposoby ich zastosowania
KR102733897B1 (ko) * 2015-12-24 2024-11-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
EP3394083B9 (en) * 2015-12-24 2022-04-27 The Regents of the University of California N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis
HRP20230833T1 (hr) 2015-12-24 2023-11-10 Respivert Limited Spojevi indolinona i njihova uporaba u liječenju fibroznih bolesti
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions

Also Published As

Publication number Publication date
RU2020111560A3 (enExample) 2021-10-29
WO2019040919A1 (en) 2019-02-28
US11839616B2 (en) 2023-12-12
EP3672598A4 (en) 2021-04-28
AU2018321926B2 (en) 2023-09-21
US20240156828A1 (en) 2024-05-16
US20210154201A1 (en) 2021-05-27
AU2018321926A1 (en) 2020-03-12
EP3672598A1 (en) 2020-07-01
RU2020111560A (ru) 2021-09-24
KR20200044873A (ko) 2020-04-29
CN111629730A (zh) 2020-09-04
US20250367207A1 (en) 2025-12-04
JP2020531511A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
US20250367207A1 (en) Ocular pharmaceutical compositions
ES2972099T3 (es) Formulación oftálmica
US11192869B2 (en) CFTR regulators and methods of use thereof
ES2370751T3 (es) Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
EA034839B1 (ru) Офтальмологический раствор
ES2909316T3 (es) Reguladores de CFTR y métodos de uso de los mismos
ES2389566T3 (es) Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
Andrés-Guerrero et al. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
RU2818087C2 (ru) Офтальмологические фармацевтические композиции
EP2072047A1 (en) Therapeutic agent for opthalmic disease
KR20130108376A (ko) 신경 보호 작용을 갖는 약제 배합

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930